Clinical & Molecular Biomedicine (CMB) is an international, peer-reviewed, open-access journal that publishes research connecting molecular discoveries with clinical applications. The journal provides a platform for scientists, clinicians, and biomedical researchers to share work that improves understanding, diagnosis, and treatment of human disease through translational medicine.

CMB promotes interdisciplinary research bridging basic molecular science and clinical medicine. It welcomes studies in translational medicine, molecular and cellular biology, clinical biochemistry, genomics and epigenetics, proteomics and metabolomics, microbiome research, molecular oncology, neurobiology, biomarker discovery, drug discovery and resistance, gene and cell therapy, precision medicine, and immunology and vaccinology.

The journal is particularly interested in studies that explain molecular mechanisms underlying human disease and show how those findings can support clinically meaningful outcomes. This includes work on disease-associated genetic and epigenetic variation, molecular biomarkers, metabolic pathways, therapeutic targets, treatment resistance, and personalized therapeutic strategies.

CMB also welcomes submissions that combine experimental, computational, and clinical approaches rather than treating those areas separately. Studies that integrate molecular data with clinical relevance, emerging biomedical technologies, or translational interpretation are especially well suited to the journal.

Across all article types, the journal values scientific rigor, ethical conduct, reproducibility, and clear relevance to molecular and clinical biomedicine. The overall aim is to publish work that not only advances biomedical knowledge, but also helps move research findings toward practical benefit in diagnosis, therapy, and patient care.